AstraZeneca doses first patients in COVID-19 therapy trial
The Phase I trial will assess the safety and pharmacokinetics of the AZD7442 monoclonal antibody combination in 48 healthy participants.
List view / Grid view
The Phase I trial will assess the safety and pharmacokinetics of the AZD7442 monoclonal antibody combination in 48 healthy participants.
The emergency use authorisation (EUA) allows the distribution and administration of COVID-19 convalescent plasma to hospitalised patients in the US.
Stempeucel®, a cell therapy for the treatment of Critical Limb Ischemia (CLI), has been approved for commercial use in India by the Drug Controller General.
Kesimpta was approved based on trial results showing the monthly injection significantly reduced the relapse rate and disability progression of MS patients compared to a currently approved treatment.
A preliminary analysis of data from the first COVID-19 pneumonia patients enrolled in the ODYSSEY trial revealed that tradipitant may expedite clinical improvement.
The European Medicines Agency (EMA) has accepted the marketing authorisation application for Evrysdi™ (risdiplam) as a treatment of spinal muscular atrophy (SMA).
Preliminary data from a study has shown that convalescent plasma therapy is safe and can combat COVID-19 in severely ill patients.
A COVID-19 vaccine dubbed “Sputnik V” has been given regulatory approval in Russia, before completing its clinical trials.
Pfizer is to manufacture and supply the investigational COVID-19 treatment remdesivir for Gilead Sciences at one of its facilities.
Tinostamustine has been granted Orphan Drug Designation by the European Commission to the treatment of T-cell prolymphocytic leukaemia (T-PLL).
Yale University and AI Therapeutics will collaborate on a Phase II trial to study LAM-002A as a COVID-19 treatment for newly diagnosed patients.
The EMA has begun to review dexamethasone to provide an opinion on the results of the RECOVERY study for the treatment of adults admitted to hospital with COVID-19.
The EMA has built up an infrastructure to allow for the monitoring of COVID-19 treatments and vaccines used in clinical practice.
Does expert knowledge on COVID-19 need to be more accessible across the globe? This article explores this issue and addresses how greater accessibility could help fight the pandemic in emerging countries.
BAN2401 will be tested in various stages of Alzheimer’s disease progression to assess if it can slow the progression of cognitive decline.